Loading...
Back to narrative

SMTI: Core Surgical Focus Will Drive Future Profit Expansion And Upside Potential

Expanding Hospital Networks And Digital Health Will Fuel Growth

SMTI logo
SMTI
AnalystConsensusTarget
Not Invested
Published 31 Mar 2025

Update shared on 14 Dec 2025

Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-22.6%
7D
1.4%

Analysts have raised their price target for Sanara MedTech to approximately $41.00 per share, reflecting slightly lower discount rate assumptions and a marginally improved outlook for the company’s long term valuation multiples.

What's in the News

  • Sanara MedTech and Biomimetic Innovations provided an update on their strategic alliance focused on advancing orthopedic solutions and commercial readiness for new products (Key Developments).
  • The company reaffirmed plans to launch OsStic Synthetic Injectable Structural Bio-Adhesive in the U.S. commercial market in the first quarter of 2027, pending FDA clearance (Key Developments).
  • OsStic received FDA Breakthrough Device Designation in December 2023, highlighting its potential to improve treatment for life-threatening or irreversibly debilitating orthopedic conditions (Key Developments).
  • Sanara is discontinuing operations of its Tissue Health Plus segment as part of a strategic realignment to focus resources on its core surgical business, with THP classified as discontinued operations going forward (Key Developments).
  • The wind-down of THP is expected to continue through the end of 2025, with total cash investment in the segment projected at $5.5 million to $6.5 million in the second half of 2025 and no material cash expenses anticipated after year end (Key Developments).

Valuation Changes

  • Fair value estimate is maintained at approximately $41.00 per share, with no meaningful change from the prior assessment.
  • The discount rate is reduced slightly from about 8.28 percent to roughly 8.13 percent, reflecting a modest decrease in perceived risk.
  • Revenue growth is kept effectively unchanged at around 13.25 percent, signaling a steady outlook for top line expansion.
  • The net profit margin remains effectively flat at approximately 32.45 percent, indicating no notable revision to long term profitability expectations.
  • The future P/E is nudged down slightly from about 9.76x to roughly 9.71x, suggesting a marginally lower valuation multiple applied to expected earnings.

Have other thoughts on Sanara MedTech?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.